 Merck announced on September 30, 2004 a worldwide withdrawal of its anti-inflammatory drug, VIOXX, following information that people taking VIOXX are twice as likely to have heart attacks and strokes as people who take older inflammatory drugs, such as Naproxen.
 |
On April 4, 2005, The FDA forced Pfizer pull it's blockbuster painkiller Bextra of the market due to cardiac concerns and serious skin conditions (some fatal). The FDA also forced numerous other popular prescription competitors like Celebrex and other NSAIDs to carry tougher new warnings that they, too, may increase the risk of heart attacks and strokes. This is a continuing Saga from last September 2004, when Merck & Company voluntarily pulled its pain reliever Vioxx from the market after studies showed increased risks of heart attacks and strokes. |
Celebrex is in the same class of drugs as Vioxx and Bextra. (On 4/8/05, Federal regulators that forced Pfizer to pull it's widely used Bextra from the market place, will allow Pfizer to continue selling it's painkiller Celebrex. The FDA is requiring that Celebrex carry the strongest possible warning, in a black box, of cardiovascular risks. Celebrex is the only remaining Cox-2 inhibitor on the market today.)
|
|
|
BREAKING NEWS
- 7/11/06 Medical Journal Corrects Fatal Vioxx Findings
- 12/08/05 Merck Deleted Vioxx Safety Info: Journal
- 12/08/05 Journal: Merck hid bad Vioxx outcomes
- 12/06/05 Merck Exec Tells of Vioxx Market Removal
- 11/17/05 Judge Sets Trial Date for Next Vioxx Suit
- 11/04/05 Merck Prevails in Second Vioxx Case on Heart Attack
- 9/29/05 Preparations Continue for Vioxx Trial
- 9/26/05 Merck Exec Testifies About Vioxx Labeling
- 9/15/05 Second Vioxx Suit Goes to Trial in N.J.
- 9/14/05 Lawyer: Man Was Active Before Taking Vioxx
- 9/14/05 Merck Accused of Hiding Risks as Vioxx Trial Opens
- 9/9/05 Merck in Vioxx Fight for Long Haul
|
